198 related articles for article (PubMed ID: 29131040)
1. Adverse Reactions to Biologics: Melanoma (Ipilimumab, Nivolumab, Pembrolizumab).
Hwang SJE; Fernández-Peñas P
Curr Probl Dermatol; 2018; 53():82-92. PubMed ID: 29131040
[TBL] [Abstract][Full Text] [Related]
2. Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor.
Belum VR; Benhuri B; Postow MA; Hellmann MD; Lesokhin AM; Segal NH; Motzer RJ; Wu S; Busam KJ; Wolchok JD; Lacouture ME
Eur J Cancer; 2016 Jun; 60():12-25. PubMed ID: 27043866
[TBL] [Abstract][Full Text] [Related]
3. Autoimmune retinopathy with associated anti-retinal antibodies as a potential immune-related adverse event associated with immunotherapy in patients with advanced cutaneous melanoma: case series and systematic review.
Heng JS; Kim JM; Jones DK; Stoessel KM; Weiss SA; Sznol M; Kluger HM; Walter SD; Silverstein NA; Pointdujour-Lim R
BMJ Open Ophthalmol; 2022; 7(1):e000889. PubMed ID: 35047671
[TBL] [Abstract][Full Text] [Related]
4. Severe cutaneous adverse reaction following COVID-19 vaccination and immunotherapy: a second hit?
Hussain K; Kawsar A; Weir J; Au L; Turajlic S; Larkin J; Fearfield L
Clin Exp Dermatol; 2022 Jan; 47(1):149-151. PubMed ID: 34260095
[No Abstract] [Full Text] [Related]
5. Survivorship in Immune Therapy: Assessing Chronic Immune Toxicities, Health Outcomes, and Functional Status among Long-term Ipilimumab Survivors at a Single Referral Center.
Johnson DB; Friedman DL; Berry E; Decker I; Ye F; Zhao S; Morgans AK; Puzanov I; Sosman JA; Lovly CM
Cancer Immunol Res; 2015 May; 3(5):464-9. PubMed ID: 25649350
[TBL] [Abstract][Full Text] [Related]
6. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Haanen JBAG; Carbonnel F; Robert C; Kerr KM; Peters S; Larkin J; Jordan K;
Ann Oncol; 2017 Jul; 28(suppl_4):iv119-iv142. PubMed ID: 28881921
[No Abstract] [Full Text] [Related]
7. Skin Reactions to Immune Checkpoint Inhibitors.
Patel AB; Pacha O
Adv Exp Med Biol; 2017; 995():175-184. PubMed ID: 28321818
[TBL] [Abstract][Full Text] [Related]
8. Alirocumab-Associated Lichenoid Reaction: A Case Report.
Román Cheuque R; Navarro-Navarro I; Jiménez-Gallo D; Linares Barrios M
Actas Dermosifiliogr; 2024 May; 115(5):522-523. PubMed ID: 37848129
[No Abstract] [Full Text] [Related]
9. [Drug-related exanthema under immunotherapy and targeted oncological therapy].
Ziemer M; Livingstone E
Dermatologie (Heidelb); 2024 Jun; 75(6):440-450. PubMed ID: 38772932
[TBL] [Abstract][Full Text] [Related]
10. Subcorneal pustular dermatosis induced by dupilumab: A novel case.
Hall S; Chew CY; Kovitwanichkanont T; Ip KH; Cahill J; Gin A; McLean CA; Gin D
Australas J Dermatol; 2024 Feb; 65(1):74-76. PubMed ID: 38009895
[No Abstract] [Full Text] [Related]
11. Small-vessel vasculitis leading to severe acute kidney injury after ipilimumab: a case report.
Duarte R; Trigo F; Luz I; Santos P
Melanoma Res; 2024 Feb; 34(1):76-79. PubMed ID: 38016155
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapies and immunotherapies in melanoma: A temporal approach to achieve optimal responses].
Braissand N; Coste I
Med Sci (Paris); 2023 Nov; 39(11):889-892. PubMed ID: 38018935
[TBL] [Abstract][Full Text] [Related]
13. Vitiligo induced by dupilumab treatment: A case series.
Ren H; Akabane AL; Kelleher K; Halverstam C; Hicks M; Schachter JR; Silverman R; Chachkin S; Sherman-Bergman S; Harris JE; Kuohung V
J Eur Acad Dermatol Venereol; 2023 Nov; 37(11):2259-2261. PubMed ID: 37114348
[No Abstract] [Full Text] [Related]
14. Combination Ipilimumab and Nivolumab for Metastatic Melanoma Associated With Ciliochoroidal Effusion and Exudative Retinal Detachment.
Tsui E; Madu A; Belinsky I; Yannuzzi LA; Freund KB; Modi YS
JAMA Ophthalmol; 2017 Dec; 135(12):1455-1457. PubMed ID: 29145556
[No Abstract] [Full Text] [Related]
15. Comparative efficacy and safety of immune checkpoint inhibitor-related therapies for advanced melanoma: a Bayesian network analysis.
Li X; Wang J; Yao Y; Yang L; Li Z; Yu C; Zhao P; Yu Y; Wang L
Oncotarget; 2017 Oct; 8(48):83637-83649. PubMed ID: 29137370
[TBL] [Abstract][Full Text] [Related]
16. Myasthenia Gravis Induced by Nivolumab: A Case Report.
Mehta JJ; Maloney E; Srinivasan S; Seitz P; Cannon M
Cureus; 2017 Sep; 9(9):e1702. PubMed ID: 29159009
[TBL] [Abstract][Full Text] [Related]
17. Smoldering myocarditis following immune checkpoint blockade.
Norwood TG; Westbrook BC; Johnson DB; Litovsky SH; Terry NL; McKee SB; Gertler AS; Moslehi JJ; Conry RM
J Immunother Cancer; 2017 Nov; 5(1):91. PubMed ID: 29157297
[TBL] [Abstract][Full Text] [Related]
18. Naevus lightening in melanoma patients under BRAF/MEK inhibitor combination therapy versus checkpoint immunotherapy: A histological and immunohistochemistry analysis.
Zhao CY; Chou S; Liu RC; Fernandez-Peñas P
Pigment Cell Melanoma Res; 2018 Mar; 31(2):341-344. PubMed ID: 29131505
[No Abstract] [Full Text] [Related]
19. Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T; Tamiya M; Tamiya A; Nakahama K; Taniguchi Y; Shiroyama T; Isa SI; Nishino K; Kumagai T; Kunimasa K; Kimura M; Suzuki H; Hirashima T; Atagi S; Imamura F
Clin Lung Cancer; 2018 Mar; 19(2):e171-e176. PubMed ID: 29133121
[TBL] [Abstract][Full Text] [Related]
20. Immune checkpoint inhibitor colitis: the flip side of the wonder drugs.
Assarzadegan N; Montgomery E; Anders RA
Virchows Arch; 2018 Jan; 472(1):125-133. PubMed ID: 29143108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
